ThermoGenesis Holdings is engaged in the development and commercialization of automated cell processing technologies for the cell and gene therapy field. Co. markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform. Co. provides the AutoXpress® and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress™ platform under development for bio-manufacturing for immuno-oncology applications. Co. has two business segments: Device Segment and Clinical Development Segment. We show 14 historical shares outstanding datapoints in our coverage of THMO's shares outstanding history.
Understanding the changing numbers of THMO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like THMO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching THMO by allowing them to research THMO shares outstanding history
as well as any other stock in our coverage universe. |
Free THMO Email Alerts:
Video: Shares Outstanding Importance
